Analyst Price Targets — DHR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 22, 2026 12:59 pm | Justin Bowers | Deutsche Bank | $240.00 | $175.03 | TheFly | Danaher price target lowered to $240 from $250 at Deutsche Bank |
| July 22, 2026 11:16 am | — | RBC Capital | $215.00 | $179.14 | TheFly | Danaher price target raised to $215 from $200 at RBC Capital |
| July 22, 2026 11:07 am | Daniel Arias | Stifel Nicolaus | $220.00 | $179.14 | TheFly | Danaher price target lowered to $220 from $260 at Stifel |
| July 22, 2026 10:34 am | — | Guggenheim | $200.00 | $179.14 | TheFly | Danaher price target lowered to $200 from $235 at Guggenheim |
| July 22, 2026 10:26 am | — | Wells Fargo | $195.00 | $179.14 | TheFly | Danaher price target lowered to $195 from $212 at Wells Fargo |
| July 6, 2026 12:41 pm | Vijay Kumar | Evercore ISI | $230.00 | $190.60 | TheFly | Danaher price target lowered to $230 from $232 at Evercore ISI |
| June 11, 2026 9:51 am | — | Piper Sandler | $200.00 | $183.63 | TheFly | Danaher initiated with a Neutral at Piper Sandler |
| June 3, 2026 9:25 am | — | HSBC | $230.00 | $176.11 | TheFly | Danaher price target lowered to $230 from $270 at HSBC |
| May 14, 2026 8:22 pm | — | RBC Capital | $200.00 | $164.54 | TheFly | Danaher resumed with an Outperform at RBC Capital |
| April 21, 2026 6:05 pm | Tycho Peterson | Jefferies | $245.00 | $194.45 | TheFly | Danaher price target raised to $245 from $240 at Jefferies |
Latest News for DHR
Ausdal Financial Partners Inc. purchased a new position in Danaher Corporation (NYSE: DHR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,452 shares of the conglomerate's stock, valued at approximately $467,000. Several other institutional investors and hedge funds have also
Bamco Inc. NY purchased a new stake in shares of Danaher Corporation (NYSE: DHR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 315,789 shares of the conglomerate's stock, valued at approximately $227,381,000. Several other hedge funds have also bought and sold shares
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Ally Financial Inc. purchased a new position in Danaher Corporation (NYSE: DHR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 47,000 shares of the conglomerate's stock, valued at approximately $8,953,000. Danaher accounts for about 1.2% of Ally Financial Inc.'s
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.